Form 8-K - Current report:
SEC Accession No. 0001193125-25-080765
Filing Date
2025-04-15
Accepted
2025-04-15 08:06:02
Documents
13
Period of Report
2025-04-14
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d940480d8k.htm   iXBRL 8-K 27504
  Complete submission text file 0001193125-25-080765.txt   150777

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mura-20250414.xsd EX-101.SCH 2869
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mura-20250414_lab.xml EX-101.LAB 17911
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mura-20250414_pre.xml EX-101.PRE 11247
15 EXTRACTED XBRL INSTANCE DOCUMENT d940480d8k_htm.xml XML 3610
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41837 | Film No.: 25837626
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)